BioNotebook: Threshold earns Merck KGaA payment, Amicus taps financing after dumped by GSK, Senesco to merge with Fabrus
This article was originally published in Scrip
Executive Summary
Threshold Pharmaceuticals earned a payment from partner Merck KGaA after hitting a target for enrolling patients in a sarcoma study. A month after being dumped by development partner GlaxoSmithKline, Amicus Therapeutics said it completed debt financing that will help it operate next year.